8 July: Biogen files for FDA license for aducanumab

On 8 July, the biotechnology company Biogen completed the submission of a biologics license application to the US Food and Drug Administration (FDA) for aducanumab as a treatment for Alzheimer’s disease (AD). Biogen requested a priority, six-month review, which has since been granted by the FDA, meaning a response will be given by 7 March 2021.

Read more »
Rate: 12345 (1) | Facebook Twitter
28 July: Impact of COVID-19 on dementia research must be addressed

On 28 July 2020, following engagement with its national members, research funders and industry partners, Alzheimer Europe issued a position statement highlighting the pressure on dementia research as a result of COVID-19. To address these issues, the position statement sets out a number of recommendations aimed at research funders and research institutions.

Read more »
Rate: 12345 (0) | Facebook Twitter
30 July: Lancet Commission identifies 12 modifiable risk factors

The 2020 Lancet Commission on dementia prevention, intervention and care identifies 12 modifiable risk factors that may account for 40% of dementia cases. Theoretically, modification of these risk factors could prevent or delay the development of dementia.

Read more »
Rate: 12345 (0) | Facebook Twitter
6 August: Register now for our virtual conference #30AEC!

Registration is now open for the 30th Alzheimer Europe Conference (#30AEC), taking place online from 20 to 22 October. Take advantage of the early bird registration fees until 15 September 2020, with a reduced registration fee of EUR 75 instead of EUR 125.

Read more »
Rate: 12345 (0) | Facebook Twitter
18 August: Are EU health policies making dementia a priority?

European Commission

Alzheimer Europe wrote to EU Vice-President for Democracy and Demography, Dubravka Šuica, and Health Commissioner, Stella Kyriakides, asking for dementia to be prioritised within EU policies, including the EU4Health programme. We have received a joint response from both offices.

Read more »
Rate: 12345 (0) | Facebook Twitter